Ocular Sciences developing daily disposable contact lens -- IPO.
This article was originally published in The Gray Sheet
OCULAR SCIENCES TO USE $17.4 MIL. OF IPO PROCEEDS FOR DEBT REPAYMENT, the soft contact lens manufacturer states in a preliminary prospectus filed with the Securities and Exchange Commission. The prospectus does not give an estimated size for the initial public offering because the number of shares to be offered and the price per share have not yet been determined. However, the filing does note that approximately $14.5 mil. would be used to repay outstanding debt under a 1996 credit agreement with Comerca Bank-California; an additional $2.9 mil. would be used to repay Chairman, President and CEO John Fruth, who "had advanced the company funds periodically, prior to 1993, to meet certain short-term operating cash requirements," the prospectus notes.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.